Boston Scientific Corp. has received CE Mark approval for its PROMUS Everolimus-Eluting Coronary stent system, complementing its already-approved TAXUS paclitaxel-eluting stent system, making the Natick-based firm the only company to receive discrete approval for two drug-eluting stent platforms in the CE region.
The new approval means BSX can effectively begin marketing the newest stent system in the 25 countries of the European Union and support registrations in other regulated countries in Asia, Latin America and Eastern Europe. The firm expects to launch the PROMUS system in Europe in 2007.
Boston Scientific Corp. is a manufacturer of medical devices.
